# DiaMedica Therapeutics (DMAC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/DMAC
## Company Profile
- Ticker: DMAC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 6.84 USD
- Market cap: 310906900.65 USD
- Last updated: 2026-08-12
## Business Overview
### Recombinant Kallikrein Therapy
DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion.
### Preeclampsia Program
Multiple Phase 2 studies are evaluating DM199 in early-onset preeclampsia. These studies are intended to assess safety, pregnancy prolongation and dose selection for a potential multinational Phase 3 program.
### Fetal Growth Restriction
An investigator-sponsored Phase 2 study evaluates whether DM199 can improve placental blood flow and fetal outcomes in pregnancies affected by fetal growth restriction.
### Acute Ischemic Stroke
ReMEDy2 is a Phase 2/3 study of DM199 in acute ischemic stroke. The trial is progressing toward an interim analysis based on a prespecified enrollment threshold.
## Why The Stock Is Moving

As of Aug 12, 2026, DMAC closed down 0.44% at $6.84. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from the first Phase 2 fetal-growth-restriction cohort in September 2026.
- First patient dosing in the Canada Phase 2 early-onset preeclampsia study in the fourth quarter of 2026.
- Interim analysis from the Phase 2/3 ReMEDy2 acute-ischemic-stroke trial in the first quarter of 2027.

## Recent News
- 2026-08-10 20:30 EST — [DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-reports-second-quarter-2026-financial-results-and-provide-a067fec0) — Source: DiaMedica Therapeutics
- 2026-08-04 20:30 EST — [DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-report-second-quarter-2026-financial-results-and-provi-e1e2e66c) — Source: DiaMedica Therapeutics
- 2026-07-17 20:30 EST — [DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e) — Source: DiaMedica Therapeutics
- 2026-06-23 12:30 EST — [DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-first-patients-dosed-in-phase-2-trial-of-dm199--97b3dc71) — Source: DiaMedica Therapeutics
- 2026-06-16 12:30 EST — [DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program](https://biopharmsignal.com/news/DMAC/diamedica-receives-fda-feedback-on-dm199-preeclampsia-nonclinical-program-34bd4bf5) — Source: DiaMedica Therapeutics